AstraZeneca's Symbicort gets US COPD approval
This article was originally published in Scrip
Executive Summary
The US FDA has approved AstraZeneca's combination asthma therapy Symbicort (budesonide plus formoterol fumarate dihydrate 160/4.5μg) for use in patients with chronic obstructive pulmonary disease (COPD).